Prenetics Global (PRE) to Release Quarterly Earnings on Monday

Prenetics Global (NASDAQ:PRE) is expected to be announcing its results before the market opens on Monday, October 6th. Analysts expect the company to announce earnings of ($0.71) per share and revenue of $21.70 million for the quarter. Prenetics Global has set its FY 2025 guidance at EPS.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings data on Friday, September 12th. The company reported ($0.82) earnings per share (EPS) for the quarter. Prenetics Global had a negative net margin of 87.92% and a negative return on equity of 31.05%. The business had revenue of $17.68 million during the quarter. On average, analysts expect Prenetics Global to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Prenetics Global Trading Down 5.2%

Shares of NASDAQ PRE opened at $14.27 on Friday. The company has a market capitalization of $185.22 million, a P/E ratio of -3.58 and a beta of 0.34. Prenetics Global has a 12 month low of $3.09 and a 12 month high of $15.35. The stock has a 50 day moving average of $9.34 and a 200-day moving average of $7.53.

Wall Street Analysts Forecast Growth

PRE has been the topic of several research analyst reports. Wall Street Zen raised shares of Prenetics Global to a “hold” rating in a research report on Saturday, July 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research report on Saturday, September 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.00.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.